Research and development facility
Global biotechnology company Novozymes is constructing a new innovation campus in Copenhagen, Denmark.
The new campus will be located in the Lyngby-Taarbæk municipality, approximately 13km north of Copenhagen. Its first phase of construction was expected to begin in October and is scheduled for completion in late-2018.
The proposed campus will host Novozymes’ biotech research and development (R&D). It has provision for expansion in future to accommodate between 2,000 and 2,500 personnel.
The project is expected to create 800 jobs in the region in the areas of R&D and other businesses. It is also expected to support education, research, and business in the Lyngby-Taarbæk municipality.
Digital tools were used in the design process with the creation of virtual buildings. In addition, 4D films were used to plan construction.
Green spaces and landscaping will be a key part of the new facility. The buildings of the campus are designed to be low-harmonic, complementing the surroundings and preserving existing forest areas.
In addition, a park and nature trail will be developed, which will be open to the public. Landscaping for the project is inspired by the adjacent Deer Park.
The buildings will feature large glass windows to provide optimal illumination and will be interlinked with corridors to support transdisciplinary collaboration.
The new campus will be built on a 140,000ft² site. It will include laboratories, a learning centre featuring teaching labs, a small cinema, and a café. The learning centre will provide opportunities for students and visitors to learn about nature and biology.
Phase I of the innovation campus will occupy 40,200m² and provide enough space for Novozymes’ operation needs until 2023, while the remaining 99,800m² area will be developed in future phases.
Construction of Phase I will include four buildings with around three floors comprising research facilities, laboratories, and other business development areas.
A parking garage with a floor space of 10,000m² will also be built in this phase.
NCC was awarded a contract to provide construction services for the first phase of the innovation campus in October.
Ramboll is serving as lead consultant for the project and is responsible for co-ordinating with Novozymes to ensure progression.
Vilhelm Lauritzen was contracted to act as the architect for the new facility, while GHB Landscape is responsible for the landscaping design.
Headquartered in Denmark, Novozymes is one of the world’s leading biotechnology companies. Founded in 2000 by a demerger from Novo Nordisk, Novozymes is engaged in the supply of industrial enzymes and microorganisms for use in agriculture, animal health, industrial cleaning, and wastewater treatment.
Novozymes achieved sales of DKK14bn ($2.06bn) in 2015 and holds a 48% market share in the industrial enzymes market. It has invested approximately 14% of its revenue on research every year, since its formation, resulting in the development of more than 100 innovative products.
Novozymes employs more than 20% of its 6,500 personnel in R&D. The number of employees has increased by 600, since 2005, to reach 2,700 in Denmark.
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…
Catalent Biologics’ manufacturing facility in Anagni, Italy will serve as the launch facility for the large-scale production and supply of…
Neopharma opened a pharmaceutical plant in Abu Dhabi, United Arab Emirates, in July 2003. The plant then entered a three-month…